Tp53 Rs28934571 Polymorphism Increases the Prognostic Risk in Hepatocellular Carcinoma

Abstract

Aim: Hepatocellular carcinoma (HCC) is considered to be the third leading cause of cancer death. The homologous gene of TP53 is significant in the occurrence and development of cancer. This study explored the relationship between TP53 rs28934571 polymorphism and HCC risk in Guangxi, China. Materials & methods: We first screened the association through bioinformatics. Additionally, a case–control study was performed to further verify the relationship between gene polymorphism and HCC risk after collecting clinical characteristics. Results: Results showed that allele A on TP53 rs28934571 was a risk factor for HCC and mutation from C to A on TP53 rs28934571 would increase the risk of poor prognosis of HCC. Conclusion: Therefore, the study concluded that TP53 rs28934571 may become a diagnostic indicator in judging the prognosis of HCC.

Identification and Validation of Novel Immunogenic Cell Death- and DNA Damage Response-Related Molecular Patterns Correlated with Immune Status and Prognosis in Hepatocellular Carcinoma

“…Somatic alteration analysis indicated that the mutation rates significantly differed between the three subtypes. Somatic mutations in TP53 are the most frequent alterations in human cancers, affect the progression and prognosis of HCC, and are associated with the immune microenvironment in HCC [ 27 , 28 ]. CTNNB1 mutations are also frequently found in HCC, where they promote Wnt/β-catenin pathway activation and facilitate tumor progression; therefore, CTNNB1 mutations can be used as biomarkers for evaluating immunotherapeutic effect in HCC [29] , [30] , [31] .…”